- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05459571
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (ZUMA-24)
A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy of Axicabtagene Ciloleucel Concomitant With Prophylactic Steroids In Subjects With Relapsed Or Refractory Large B-Cell Lymphoma In The Outpatient Setting
The goal of this clinical study was to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants who completed at minimum 18 months follow up were transitioned to a separate long-term follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up assessments.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
-
Los Angeles, California, United States, 90025
- UCLA
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Colorado Blood Cancer Institute
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland Greenebaum Comprehensive Cancer Center
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- John Theurer Cancer Center at Hackensack University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45242
- Oncology Hematology Care Clinical Trials, LLC
-
-
South Carolina
-
Greenville, South Carolina, United States, 29615
- Prisma Health - Upstate
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology, PLLC
-
Nashville, Tennessee, United States, 37232
- Henry-Joyce Cancer Clinic
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Methodist Healthcare System of San Antonio
-
-
Utah
-
Murray, Utah, United States, 84107
- Intermountain Healthcare
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute, University of Utah
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Health System
-
Norfolk, Virginia, United States, 23502
- Virginia Oncology Associates
-
Richmond, Virginia, United States, 23219
- Virginia Commonwealth University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
-
Histologically confirmed large B-cell lymphoma (LBCL), including the following types defined by World Health Organization (WHO) 2016 classification, by local pathology laboratory assessment, are eligible as defined below:
- Diffuse large B-cell lymphoma (DLBCL) not otherwise specified.
- High-grade B-cell lymphoma (HGBL) with or without MYC and BCL2 and/or BCL6 rearrangement.
- DLBCL associated with chronic inflammation; Epstein-Barr virus (EBV) + DLBCL.
- Primary mediastinal (thymic) LBCL.
- Primary cutaneous DLBCL, leg type.
- Transformation of follicular lymphoma to DLBCL will also be included.
-
Relapsed or refractory disease after 1 or more lines of therapy.
-
Individuals must have received adequate prior therapy including:
- Anti-CD20 monoclonal antibody AND
- An anthracycline-containing chemotherapy regimen.
-
At least 1 measurable lesion according to the Lugano Response Criteria for Malignant Lymphoma. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
-
Individual agrees to outpatient treatment setting and to adhere to the prespecified clinical monitoring requirements.
Key Exclusion Criteria:
- History of autologous or allogeneic stem cell transplant.
- Prior cluster of differentiation (CD)19 targeted therapy.
- Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy.
- Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management. Simple urinary tract infection and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the Kite medical monitor.
- Individuals with detectable cerebrospinal fluid malignant cells, brain metastases, or with a history of central nervous system (CNS) lymphoma or primary CNS lymphoma. DLBCL epidural involvement should be considered as positive CNS disease.
- In the investigator's judgment, the individual is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Axicabtagene Ciloleucel
Participants will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m^2/day and fludarabine 30 mg/m^2/day) over 3 days (Days -5, -4, and -3) followed by prophylactic corticosteroid treatment with 10 mg dexamethasone on Day 0 (prior to axicabtagene ciloleucel), Day 1, and Day 2. Participants will receive axicabtagene ciloleucel consisting of a single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells on Day 0 (following dexamethasone 10 mg) at a target dose of 2 x 10^6 cells/kg. |
Administered intravenously Administered intravenously Administered intravenously
Other Names:
Administered orally or intravenously |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Treatment-emergent Cytokine Release Syndrome (CRS) as Per Severity
Time Frame: Up to 2.2 years
|
CRS were identified via collection of the syndrome on a case report form specifically designed to collect CRS. Individual symptoms of CRS were separately collected on the Adverse Event (AE) log and were linked to the CRS syndrome. CRS events were graded per the revised grading system proposed by Lee et al 2014. Grade 1: Symptoms are not life threatening and require symptomatic treatment only; Grade 2: Symptoms require and respond to moderate intervention; Grade 3: Symptoms require and respond to aggressive intervention; Grade 4: Life-threatening symptoms; Grade 5: Death. |
Up to 2.2 years
|
|
Percentage of Participants With Treatment-emergent Neurologic Events as Per Severity
Time Frame: Up to 2.2 years
|
Neurological events were identified with a search strategy based on known neurologic toxicities associated with anti-CD19 immunotherapy. The search strategy focused on central nervous system toxicity, without regard to temporal relationship and concomitant conditions. Neurologic events were graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening consequences, Grade 5: Death. |
Up to 2.2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Onset of CRS Following Axicabtagene Ciloleucel Administration
Time Frame: Up to 2.2 years
|
Time to onset was defined as the earliest start date of CRS minus the axicabtagene ciloleucel infusion date plus 1. Participants without CRS by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. Kaplan-Meier (KM) estimates was used for analyses. |
Up to 2.2 years
|
|
Time to Onset of Neurologic Events Following Axicabtagene Ciloleucel Administration
Time Frame: Up to 2.2 years
|
Time to onset was defined as the earliest start date of neurologic event minus the axicabtagene ciloleucel infusion date plus 1. Participants without neurologic event by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. KM estimates was used for analyses. |
Up to 2.2 years
|
|
Duration of CRS Following Axicabtagene Ciloleucel Administration
Time Frame: Up to 2.2 years
|
Duration was defined as the latest end date of CRS minus the start date of the earliest CRS plus 1. Participants with unresolved or ongoing CRS by the data cutoff were censored at death date if participant died or last known alive date if participant is still alive; participants who withdrew consent, were censored at end of study date. KM estimates was used for analyses. |
Up to 2.2 years
|
|
Duration of Neurologic Events Following Axicabtagene Ciloleucel Administration
Time Frame: Up to 2.2 years
|
Duration was defined as the latest end date of neurologic event minus the start date of the earliest neurologic event plus 1. Participants with unresolved or ongoing neurologic event by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. KM estimates was used for analyses. |
Up to 2.2 years
|
|
Percentage of Participants Hospitalized Within 72 Hours of Axicabtagene Ciloleucel Infusion
Time Frame: Within 72 hours of axicabtagene ciloleucel infusion on Day 0
|
Hospitalized within 72 hours refers to 72 hours from the time when axicabtagene ciloleucel infusion starts. |
Within 72 hours of axicabtagene ciloleucel infusion on Day 0
|
|
Percentage of Participants Hospitalized Within 4 Days of Axicabtagene Ciloleucel Infusion
Time Frame: Within 4 days of axicabtagene ciloleucel infusion (from Day 0 to Day 3)
|
Hospitalization within 4 days refers to the period from Day 0 to Day 3 following axicabtagene ciloleucel infusion. |
Within 4 days of axicabtagene ciloleucel infusion (from Day 0 to Day 3)
|
|
Percentage of Participants Hospitalized Within 7 Days of Axicabtagene Ciloleucel Infusion
Time Frame: Within 7 days of axicabtagene ciloleucel infusion (from Day 0 to Day 6)
|
Hospitalization within 7 days refers to the period from Day 0 to Day 6 following axicabtagene ciloleucel infusion. |
Within 7 days of axicabtagene ciloleucel infusion (from Day 0 to Day 6)
|
|
Percentage of Participants Hospitalized Within 14 Days of Axicabtagene Ciloleucel Infusion
Time Frame: Within 14 days of axicabtagene ciloleucel infusion (from Day 0 to Day 13)
|
Hospitalization within 14 days refers to the period from Day 0 to Day 13 following axicabtagene ciloleucel infusion. |
Within 14 days of axicabtagene ciloleucel infusion (from Day 0 to Day 13)
|
|
Percentage of Participants Hospitalized Within 30 Days of Axicabtagene Ciloleucel Infusion
Time Frame: Within 30 days of axicabtagene ciloleucel infusion (from Day 0 to Day 29)
|
Hospitalization within 30 days refers to the period from Day 0 to Day 29 following axicabtagene ciloleucel infusion. |
Within 30 days of axicabtagene ciloleucel infusion (from Day 0 to Day 29)
|
|
Duration of Initial Hospitalization After Axicabtagene Ciloleucel Infusion
Time Frame: Up to 2.2 years
|
Up to 2.2 years
|
|
|
Percentage of Intensive Care Unit (ICU) Admitted Participants
Time Frame: Up to 30 days
|
Up to 30 days
|
|
|
Duration of ICU Admission During First Hospitalization After Axicabtagene Ciloleucel Infusion
Time Frame: Up to 2.2 years
|
Up to 2.2 years
|
|
|
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Up to 2.2 years
|
An AE was defined as any untoward medical occurrence in a clinical trial participant. The event did not necessarily have a relationship with study treatment. TEAEs were defined as any adverse event with onset on or after the axicabtagene ciloleucel infusion. |
Up to 2.2 years
|
|
Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (TESAEs)
Time Frame: Up to 2.2 years
|
A serious adverse event (SAEs) was defined as an event that, at any dose, resulted in death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. TESAEs were defined as any serious adverse event with onset on or after the axicabtagene ciloleucel infusion. |
Up to 2.2 years
|
|
Number of Participants With European Quality of Life Five Dimensions Five Levels Scale (EQ-5D-5L) Score
Time Frame: Baseline, Week 4, Month 3, Month 6
|
The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and EuroQoL visual analogue scale (EQ-VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Here Baseline corresponds to Screening (within 28 days before enrollment/leukapheresis). |
Baseline, Week 4, Month 3, Month 6
|
|
EQ-5D-5L Visual Analogue Scale (EQ-VAS) Score
Time Frame: Baseline, Week 4, Month 3, Month 6
|
The EQ-VAS is a vertical VAS for recording self-rated current Health-Related Quality of Life (HRQoL) state reported from 0, described as "the worst health you can imagine", to 100, described as "the best health you can imagine" Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ-VAS indicate better health. Here Baseline corresponds to Screening (within 28 days before enrollment/leukapheresis). |
Baseline, Week 4, Month 3, Month 6
|
|
Percentage of Participants With Objective Response (OR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Time Frame: Up to 2.5 years
|
OR: complete response (complete metabolic response[CMR]; complete radiologic response[CRR]) or partial response (partial MR [PMR]; partial RR [PRR]). CMR: positron emission tomography(PET) 5-point scale(5-PS) of 1-3 with/without residual mass; no new sites/evidence of fluorodeoxyglucose(FDG)-avid disease in bone marrow(BM).CRR: target nodes/nodal masses regressed to ≤1.5cm in longest transverse diameter(LDi) of lesion;no extra lymphatic sites;absent nonmeasured lesion(NMLs);organ enlargement regress to normal;no new sites;BM normal by morphology.PMR:5PS scores 4/5 with reduced uptake compared to baseline,residual masses of any size;no new sites;residual uptake higher than uptake in normal BM,reduced compared with baseline.PRR:≥50% decrease in sum of product of perpendicular diameters up to 6 target measurable nodes & extranodal sites;absent/normal,regressed but no increase of NMLs;spleen regressed by >50%;no new sites of disease. 95% CI were calculated by Clopper-Pearson method. |
Up to 2.5 years
|
|
Percentage of Participants With Complete Response (CR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Time Frame: Up to 2.5 years
|
Complete response is defined as participants with CMR and CRR. CMR: PET 5-PS scores of 1-3 with or without residual mass; no new sites/evidence of FDG-avid disease in bone marrow. CRR: target nodes/nodal masses regressed to ≤ 1.5cm in LDi of lesion; no extra lymphatic sites; absent NMLs; organ enlargement regress to normal; no new sites; and bone marrow normal by morphology. 95% CI were calculated by Clopper-Pearson method. Percentages were rounded off. |
Up to 2.5 years
|
|
Duration of Response (DOR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Time Frame: Up to 2.5 years
|
DOR is the time from first OR to disease progression (PD) or death from any cause. OR is defined in outcome measure (OM) 19. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi >1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by > 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses. |
Up to 2.5 years
|
|
Progression-free Survival (PFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Time Frame: Up to 2.5 years
|
PFS was defined as the time from axicabtagene ciloleucel infusion date to the date of disease progression or, if no disease progression, the date of death due to any cause. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi >1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by > 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses. |
Up to 2.5 years
|
|
Event Free Survival (EFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Time Frame: Up to 2.5 years
|
EFS is defined as the time from axicabtagene ciloleucel infusion to the earliest date of disease progression, commencement of new anti-lymphoma therapy (excluding SCT), or death from any cause. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi >1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by > 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses. |
Up to 2.5 years
|
|
Overall Survival (OS)
Time Frame: Up to 2.5 years
|
OS was defined as the time from the axicabtagene ciloleucel infusion date to the date of death from any cause. KM estimates was used for analyses. |
Up to 2.5 years
|
|
Peak Serum Levels of Homeostatic/Proliferative Cytokines: Interleukin (IL)-2, IL-7, and IL-15
Time Frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
Peak is defined as the maximum analyte level in blood measured after infusion up to Day 28. |
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
|
Peak Serum Levels of Inflammatory and Immune Modulating Cytokines: Interferon Gamma (IFN-γ), IL-1, IL-6, IL- 13, IL-17, IL-1RA, Granulocyte-macrophage Colony Stimulating Factor (GM-CSF), Tumor Necrosis Factor-Alpha (TNF-α), IL-12p40, and IL-12p70
Time Frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28. |
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
|
Peak Serum Levels of Immune Effector Molecules: Granzyme A and Granzyme B
Time Frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28. |
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
|
Peak Serum Levels of Immune Effector Molecules: Perforin
Time Frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28. |
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
|
Peak Serum Levels of Acute Phase Response Proteins: Serum Amyloid A (SAA)
Time Frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28. |
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
|
Peak Serum Levels of the Acute Phase Response Proteins: C-Reactive Protein (CRP)
Time Frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28. |
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
|
Peak Serum Levels of the Acute Phase Response Proteins: Ferritin
Time Frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28. |
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
|
Peak Serum Levels of the Immune Activation Marker: Soluble IL-2 Receptor Alpha (sIL-2Rα)
Time Frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28. |
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
|
Peak Serum Levels of Chemokines: IL-8, C-X-C Motif Chemokine Ligand-10 (CXCL-10), and Monocyte Chemotactic Protein-1 (MCP-1)
Time Frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28. |
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
|
|
Peak Blood Levels of Axicabtagene Ciloleucel Chimeric Antigen Receptor (CAR) T-cells
Time Frame: Up to 24 months
|
Peak is defined as the maximum number of CAR T-cells in blood measured after axicabtagene ciloleucel infusion. |
Up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kite Study Director, Kite, A Gilead Company
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Pathological Conditions, Signs and Symptoms
- Recurrence
- Organic Chemicals
- Hydrocarbons
- Polycyclic Compounds
- Pregnadienes
- Pregnanes
- Steroids
- Fused-Ring Compounds
- Steroids, Fluorinated
- Phosphoramide Mustards
- Nitrogen Mustard Compounds
- Mustard Compounds
- Hydrocarbons, Halogenated
- Phosphoramides
- Organophosphorus Compounds
- Pregnadienetriols
- Dexamethasone
- Cyclophosphamide
- fludarabine
- axicabtagene ciloleucel
Other Study ID Numbers
- KT-US-482-0137
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
IPD Sharing Time Frame
18 months after study completion
IPD Sharing Access Criteria
A secured external environment with username, password, and RSA code.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.